|
Chỉ định và Liều dùng
Intravenous
Facilitate endotracheal intubation, Muscle relaxant in general anaesthesia Adult: Initial dose: 80-100 mcg/kg. Subsequent doses: 10-20 mcg/kg. Initial dose following suxamethonium admin or in patients at high risk: 50-60 mcg/kg. Initial dose for caesarean section: 35 mcg/kg.
|
|
Chống chỉ định
Hypersensitivity.
|
|
Thận trọng
Pulmonary disease, respiratory insufficiency, asthma, neuromuscular disease, dehydration, severely ill patients, hepatic or renal impairment. Doses in obese patients should be based on patient's ideal body weight. Pregnancy, lactation.
|
|
Tác dụng không mong muốn
Transient hypotension, bradycardia, reduced cardiac output.
Potentially Fatal: Anaphylactic reactions and malignant hyperthermia. |
|
IV/Parenteral: C
|
|
Quá liều
Prolonged apnoea due to paralysis of the intercostal muscles and diaphragm, with CV collapse and effects of histamine release.
|
|
Tương tác
Actions antagonised by cholinesterases and long term carbamazepine, phenytoin or corticosteroids usage. Enhanced block when used with drugs that have neuromuscular blocking activity such as lidocaine, quinidine, verapamil and aminoglycosides.
Potentially Fatal: Effects enhanced by volatile inhalational anaesthetics, ketamine (IV), antiarrhythmics, antibacterials, K depleting diuretics, parenteral Mg salts. |
|
Tác dụng
Description:
Mechanism of Action: Pipecuronium bromide is an aminosteroidal competitive neuromuscular blocker. It does not have significant CV adverse effects or histamine-related effects. Onset: Dose-dependent: 2.5-3 min. Duration: Dose-dependent: 30 min-2 hr. Pharmacokinetics: Distribution: Vd: 0.25 L/kg. Metabolism: Converted to 3-desacetyl (less active). Excretion: Via urine (as unchanged); 1.7-2.3 hr (elimination half-life). |
|
Phân loại MIMS
|
Đăng xuất
